Malignant mesothelioma, an aggressive cancer mainly caused by asbestos, mainly affects the pleura, the lining of the lungs. It also affects the peritoneum, which is the lining of the abdomen. It is very tough to diagnose mesothelioma, which leads to underdiagnosis of the disease. A study in Brazil’s Sao Paulo[…]
Mesothelioma
Evaluating Ivonescimab As a Potential Treatment for Pleural Mesothelioma Patients Whose Cancer Has Returned After Previous Immunotherapy and Chemotherapy (Bi-MAPS)
Primary Outcome Measures The analysis of the primary efficacy endpoint will be conducted in all eligible patients, based on the disease control rate (DCR) at 12 weeks according to mRECIST 1.1 for mesothelioma, which was defined as the proportion of patients with compete response (CR), partial response (PR) or stable[…]
The Diagnostic Accuracy and Clinical Value of FAPI PET in Pleural Mesothelioma (FAPI-PM)
Primary Outcome Measures The diagnostic performance (sensitivity, specificity, positive predicative value, negative predicative value, and overall diagnostic accuracy – all parameters in %). in of FAPI PET compared to routine imaging modalities, including FDG PET/CT, in suspected PM lesions. Secondary Outcome Measures Calculate the proportion of patients where the location[…]
MARS 2 Trial for Mesothelioma
Malignant pleural mesothelioma is a deadly cancer mainly caused by asbestos exposure. It is a hard-to-treat cancer due to its aggressiveness. The cancer affects the pleura, which is the membrane that covers the lungs. A trial known as MARS 2 tried to find out if extended pleurectomy and decortication could[…]
The Diagnostic Accuracy and Clinical Value of FAPI PET in Pleural Mesothelioma (FAPI-PM)
Primary Outcome Measures Calculate the proportion of patients where the location of the intended pleural biopsy is altered due to FAPI PET/CT replacing FDG PET/CT. Secondary Outcome Measures Compare the cancer stage (IASCL 9th edition TNM-classification) as determined by FAPI PET/CT compared to conventional imaging (including FDG PET/CT) at primary[…]
Improving Mesothelioma Diagnosis
Malignant mesothelioma, an aggressive cancer mainly caused by asbestos exposure, mostly affects the pleura. The pleura is the membrane that surrounds the lungs. It can also harm tissues like the peritoneum, which is a membrane that surrounds the abdomen. Due to its rare nature and shared symptoms with other illnesses,[…]
Changing Gut Bacteria Could Improve Effectiveness of Certain Treatments for Mesothelioma
A new cancer study has found that certain gut bacteria could influence a person’s immune system when fighting mesothelioma, an aggressive cancer of the linings of certain areas of the body including the lungs, abdomen, heart, and testicles. This has led experts to believe that in future cases of mesothelioma,[…]
New Blood Test for Mesothelioma
Mayo Clinic researchers have created a new blood test that is better able to detect mesothelioma. The result could be earlier diagnoses. It could also lead to new options for targeted therapies. The test works by finding complex DNA patterns that are common in mesothelioma cells. The new approach is[…]
Keytruda and Chemotherapy Approved for the Treatment of Mesothelioma
A new first line treatment was approved by the U.S. Food and Drug Administration for the treatment of pleural mesothelioma that cannot be removed by surgery. The approval is specifically for Keytruda alongside pemetrexed and platinum chemotherapy. The approval follows the promising results in phases 2 and 3 of the[…]
Study of ISM6331 in Participants With Advanced/Metastatic Malignant Mesothelioma or Other Solid Tumors
This is a Phase 1, open-label, multicenter, FIH study to evaluate the safety, tolerability, recommended Phase 2 dose (RP2D), PK/PD, and preliminary anti-tumor activity of ISM6331 in participants with advanced or metastatic malignant mesothelioma or other solid tumors. The study consists of two parts, a dose escalation part (Part 1) and a dose selection optimization part (Part 2).
